a nonsignificant trendp = 0.47
However, bevacizumab treatment showed a nonsignificant trend toward increased perforation rates compared with chemotherapy alone (12.5% vs. 8%, respectively; p = 0.47).
However, bevacizumab treatment showed a nonsignificant trend toward increased perforation rates compared with chemotherapy alone (12.5% vs. 8%, respectively; p = 0.47).